Window of opportunity with abatacept in Rheumatoid arthritis-associated interstitial lung disease: A multicentre study of 526 patients.
Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a major cause of morbidity and mortality, and optimal treatment strategies remain unclear. Abatacept (ABA) is supported by observational evidence, but the impact of early initiation on pulmonary outcomes is un…